Featuring CGIX, OXYS, and VRTT

In this week’s edition of “The RedChip Money Report” we’re featuring Cancer Genetics (NASDAQ: CGIX), OxySure Systems (OTCQB: OXYS), and Viatar CTC Solutions (OTCQB: VRTT).

Cancer Genetics, an emerging leader in DNA-based diagnostics, is at the center of the paradigm shift in healthcare. It’s growing portfolio of proprietary cancer tests are improving outcomes for major biopharma clients and patients alike. With 191% year-over-year revenue growth reported for the first half of 2015, this is a stock every investor should know.

OxySure Systems, a provider of emergency oxygen technology solutions, continues to execute on its business model. In this week’s newsletter we highlight recent news about a paper published in the Journal of Emergency Medical Services that paves the way for “public/first aid” oxygen usage, prior to the arrival of first responders. This is big news that could lead to accelerating sales for OxySure in the coming quarters.

We’re also pleased to welcome Viatar CTC Solutions to the RedChip Nation this week. VRTT has groundbreaking technology that is designed to improve outcomes for the large and under-served metastatic cancer market. As you’ll see in our recently published fact sheet on VRTT, they have built a strong foundation, and we expect multiple milestones to be reached over the next 12-18 months.

For Further Information, Contact:
RedChip Companies, Inc.
1017 Maitland Center Commons Blvd. Maitland, FL 32751
1 (800) 733-2447
Fax: (407) 644-0758
[email protected]
Visit: www.RedChip.com

Disclaimer |Privacy